Q-omics provides the consensus-scored KRTCAP2P1 profile across patient tissues and cancer cell-line models. KRTCAP2P1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KRTCAP2P1 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, KRTCAP2P1 RNA expression shows 11,987 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, COAD, and TGCT as cancer lineages where KRTCAP2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTCAP2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTCAP2P1 survival associations across molecular data types. KRTCAP2P1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTCAP2P1 RNA expression–survival associations across cancer types. High KRTCAP2P1 expression shows unfavorable associations in UVM, ACC and LIHC, but favorable associations in UCEC, LUSC and TGCT. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for KRTCAP2P1 RNA expression.
This table summarizes KRTCAP2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRTCAP2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTCAP2P1 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, BRCA, LUAD and UCEC. The COAD box plot shows higher KRTCAP2P1 RNA expression in tumor versus normal tissue (log2 FC = +1.541, t-test p < 0.001).
This table shows molecular features associated with KRTCAP2P1 in patient tissues and cancer cell lines. In patient samples, KRTCAP2P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
